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Background. Host responses to infection are critical determinants of disease severity and clinical outcome. The development of
tools to risk stratify children with malaria is needed to identify children most likely to beneﬁt from targeted interventions.
Methods. This study investigated the kinetics of candidate biomarkers of mortality associated with endothelial activation and
dysfunction (angiopoietin-2 [Ang-2], soluble FMS-like tyrosine kinase-1 [sFlt-1], and soluble intercellular adhesion molecule-1
[sICAM-1]) and inﬂammation (10 kDa interferon γ-induced protein [CXCL10/IP-10] and soluble triggering receptor expressed
on myeloid cells-1 [sTREM-1]) in the context of a randomized, double-blind, placebo-controlled, parallel-arm trial evaluating in-
haled nitric oxide versus placebo as adjunctive therapy to parenteral artesunate for severe malaria. One hundred eighty children aged
1–10 years were enrolled at Jinja Regional Referral Hospital in Uganda and followed for up to 6 months.
Results. There were no differences between the 2 study arms in the rate of biomarker recovery. Median levels of Ang-2, CXCL10,
and sFlt-1 were higher at admission in children who died in-hospital (n = 15 of 180; P < .001, P = .027, and P = .004, respectively).
Elevated levels of Ang-2, sTREM-1, CXCL10, and sICAM-1 were associated with prolonged clinical recovery times in survivors. The
Ang-2 levels were also associated with postdischarge mortality (P < .0001). No biomarkers were associated with neurodisability.
Conclusions. Persistent endothelial activation and dysfunction predict survival in children admitted with severe malaria.
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Malaria remains a leading cause of global morbidity andmortality
and results in an estimated 306 000 deaths in African children
under 5 years of age annually [1]. Severe malaria, which affects
children during critical periods of brain development, is associat-
ed with long-term neurologic, cognitive, attention, and memory
deﬁcits in survivors [2–5].
Although reductions inmalaria mortality are likely to continue
from sustained investment in malaria control programs, mortal-
ity remains unacceptably high. The development and implemen-
tation of tools to rapidly stratify children according to risk-groups
are urgently needed. In a recent study, we evaluated the ability of
clinical risk scores developed in resource-constrained settings to
predict all-cause in-hospital mortality in a cohort of Ugandan
children with fever [6–8]. The Lambaréné Organ Dysfunction
Score (LODS) was the simplest to compute, did not require
equipment, and had the best prediction. Host biomarkers that
could be integrated with simple clinical disease severity scores
(eg, LODS) to (1) improve patient triage and (2) identify children
most likely to beneﬁt from targeted interventions would repre-
sent an important advance in improving outcomes in severe ma-
laria. Furthermore, validated biomarkers of disease pathways that
contribute to severe malaria would facilitate the design and con-
duct of clinical trials of pathway-speciﬁc interventions to improve
outcome.
Investigations into the pathophysiology of severe malaria high-
light the importance of host immune response in determining
clinical outcome. Excessive proinﬂammatory responses and sys-
temic endothelial activation have been associated with disease se-
verity and mortality in several studies [9–17]. In this study, we
further explore a panel of biomarkers associated with endothelial
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activation and dysfunction (angiopoietin-2 [Ang-2], soluble
FMS-like tyrosine kinase-1 [sFlt-1], and soluble intercellular ad-
hesion molecule-1 [sICAM-1]) and inﬂammation (10 kDa inter-
feron gamma-induced protein [CXCL10/IP-10] and soluble
triggering receptor expressed on myeloid cells-1 [sTREM-1]).
These biomarkers represent a panel of candidate biomarkers of
mortality previously identiﬁed in Ugandan children with severe
malaria [14].
METHODS
Trial Design
This study is a secondary analysis of a randomized, double-blind,
placebo-controlled trial evaluating inhaled nitric oxide (iNO) as
an adjunctive therapy for severe malaria as described elsewhere
[18, 19]. All children were treated with intravenous artesunate.
The primary objective of this study was to evaluate the associa-
tion between biomarker levels and trial arm by intention-to-treat
analysis. Secondary objectives were to evaluate the association be-
tween the biomarkers, disease severity, clinical recovery, and
mortality.
The study was approved by Makerere University School of
Medicine Research Ethics Committee, Uganda National Council
on Science and Technology, Ugandan National Drug Authority,
and the University Health Network (Toronto, Canada). All par-
ents or guardians provided written informed consent (Clinical-
Trials.gov identiﬁer NCT01255215).
Study Participants
The study was performed at Jinja Regional Referral Hospital in
mid-eastern Uganda [20]. Children aged 1–10 years were eligible
if they had a rapid diagnostic test positive for both Plasmodium
falciparum histidine-rich protein 2 and lactate dehydrogenase
([LDH] First Response Malaria Ag. Premier Medical Corporation
Limited, India) [21] as well as selected criteria for severe malaria
including the following: repeated seizures (2 or more generalized
seizures in 24 hours), prostration (child unable to sit unsupported
or stand), impaired consciousness (Blantyre coma score [BCS] <5),
and respiratory distress (age-related tachypneawith sustained nasal
ﬂaring, deep breathing, or subcostal retractions). Well known se-
verity criteria for severe malaria, including severe anemia and
hypoglycemia where not inclusion criterial in this trial, although
they may have occurred alongside any of the other inclusion crite-
ria. Exclusion criteria included the following: severe anemia
(hemoglobin <5 g/dL or pallor) without any other features of
severe malaria; known chronic illness; severe malnutrition, hemo-
globinopathy, and clinical suspicion of bacterial meningitis [19].
Laboratory Procedures
Blood was drawn at admission and daily during the ﬁrst 72 hours
of hospital admission. Samples were sent to a central laboratory
for quantiﬁcation of parasite density and for complete blood
counts [21]. Ethylenediaminetetraacetic acid plasma was stored
at −80°C until biomarker testing, as described previously [21].
Statistical Analysis
Statistical analyses were done with SPSS version 20, Graph Pad
Prism version 6, MedCalc version 13.1.2, and R (version 1.3.2,
2014). The longitudinal course of biomarkers was compared be-
tween study arms using linear mixed-effects (LME) models ac-
cording to a prespeciﬁed analytic approach [18].
Data are presented as medians (interquartile range) and ana-
lyzed non-parametrically. The relationship between continuous
variables and mortality was assessed using the Mann-Whitney
U test. The Jonckheere-Terpstra test for ordered alternatives was
used to assess (1) a linear trend between biomarker levels and BCS
or LODS and (2) biomarker levels by quartile and time to clinical
recovery. Categorical data were analyzed using Pearson’s χ2 test.
The Friedman’s test with Dunn’s multiple comparison test was
used to test for changes in biomarker levels across hospitalization.
To assess the ability of the clinical and biomarker models to dis-
criminate between survivors and nonsurvivors, logistic regression
was used, and the predicted probabilities were used to generate
non-parametric receiver operating characteristic (ROC) curves.
The areas under ROC (AUC) curves were compared using the
method of DeLong.
The LME analysis of the in-hospital longitudinal course of log
(Ang-2) over time in patients who died after discharge but within
6 months of illness versus those who were known to be alive at 6
months was performed. Time and survival group (death or sur-
vival at 6 months) were entered as ﬁxed effects without an inter-
action term. Intercepts and slopes were modeled for each subject
as random effects. Visual inspection of residual plots did not re-
veal deviations from homoscedasticity or normality. P values
were obtained by likelihood ratio tests of the full model (includ-
ing survival group) against the model without the survival group.
RESULTS
Longitudinal Assessment of Biomarkers From Admission to Discharge
One hundred eighty children were enrolled in the clinical trial
and randomized to receive either iNO (n = 88) or placebo
(n = 92) (Figure 1). For a description of the trial population,
see Table 1.
There were no differences in clinical recovery times, develop-
ment of complications, or outcomes between trial arms [19]. To
determine whether iNO therapy affected biomarker levels, we
generated LME models for each biomarker. Because mortality
was low and comparable between groups (8.0% and 9.9% in
the iNO and placebo groups, respectively), analysis was per-
formed on survivors. Biomarker levels did not differ between
treatment arms for any markers (P > .05); therefore, biomarker
data were pooled in subsequent analyses.
All biomarkers were higher at presentation and decreased
over hospitalization ( P < .05; Figure 2). Using the day 14 sample
as our normative value (convalescent sample), the majority of
markers (Ang-2, CXCL10, sFlt-1, and sTREM-1) returned to
baseline by day 3 in hospital (P > .05 day 3 vs day 14). Venous
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lactate had faster recovery, normalizing within 12 hours of ad-
mission, whereas sICAM-1 remained elevated on day 4.
We evaluated the association between admission biomarker
levels and time to clinical recovery comparing the median recov-
ery times across quartiles of biomarkers relative to the following:
(1) time to ﬁrst feed, (2) time to fever resolution, (3) time to lo-
calize pain, (4) time to regain consciousness (BCS = 5), (5) time
to ﬁrst sit, and (6) duration of hospitalization (Table 2). Time to
ﬁrst feed, time to ﬁrst sit, and time to regain consciousness in-
creased across quartiles of Ang-2 and sTREM-1, whereas time
to fever resolution increased across quartiles of sICAM-1 and
CXCL10 (P < .05 for all comparisons). Increased time to ﬁrst
sit and increased duration of hospitalization were observed across
quartiles of sICAM-1.
Clinical and Laboratory Findings Associated With In-hospital and
Postdischarge Mortality
A description of the study cohort and an evaluation of factors
associated with in-hospital and postdischarge mortality are
shown in Table 1. The majority of deaths occurred within 24
hours of admission (9 of 15 in-hospital deaths, 60%). Only 1
child who died in-hospital survived beyond day 2. Acidosis
was common with 34.3% of all children having lactate >5
mmol/L at admission; however, acidosis was more common in
children who died (66.7%) and was associated with an increased
Figure 1. Study flowchart for secondary biomarker analysis. Abbreviations: iNO, inhaled nitric oxide; RDT, rapid diagnostic test.
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risk of death (relative risk [RR], 1.2; 95% conﬁdence interval
[CI], 1.0–1.3). Presenting signs associated with in-hospital mor-
tality were severe anemia, coma, features of respiratory distress,
and shock (P < .05, χ2 test). The interrelationships between the
most common clinical prognostic signs are shown in Figure 3.
Overall, children who died in-hospital had more severe malaria
criteria at presentation than children who survived (P < .0001;
Table 1).
All children who died after hospital discharge initially presented
with severe anemia, were more likely to have jaundice (P = .051),
and had lower parasitemia at presentation than survivors (Table 1,
Figure 3). Elevated plasma LDH levels were associated with both
in-hospital and postdischarge mortality. There was a trend towards
an increased number of transfusions during hospitalization in chil-
dren who died postdischarge (median number of transfusions: in
survivors, 1; in postdischarge deaths, 2; P= .079). Repeat hemoglobin
Table 1. Description of Cohorta
Characteristics Cohort (n = 180) In-hospital Mortality (n = 15) Postdischarge Mortality (n = 8)
Demographics and History
Age, years 2.0 (1.0–3.0) 1.1 (1.0–2.0) 1.1 (1.0–2.8)
Female sex 78 (43.3) 7 (53.3) 5 (62.5)
Weight-for-age z-score −1 (−2, 0) −1 (−2, 0) 0 (−2, 1)
Height-for-age z-score −2 (−3, 0) −2 (−3, 0) 0 (−2, 1)
Weight-for-height z-score 0 (−1, 1) −1 (−2, 0) 0 (−1, 1)
Fever before enrollment, days 3.0 (2.0–4.0) 3.0 (2.0–4.0) 2.0 (2.0–2.8)
Characteristics at admission
Temperature, °C 37.9 (37.0–38.8) 37.0 (36.6–37.8)† 37.8 (36.9–39.0)
Heart rate, bpm 162 (144–179) 173 (156–183) 156 (155–163)
Respiratory rate, bpm 48 (38–62) 61 (47–77)† 55 (40–64)
Systolic blood pressure, mmHg 110 (100–120) 100 (90–126)† 120 (120–130)†
Blantyre coma score (BCS) 2 (2–3) 2 (1–2) 3 (2–4)
Lambaréné Organ Dysfunction Score 2 (1–3) 3 (2–3) 1.5 (0.3–2.0)
Prostrate 164/180 (91.1) 15/15 (100.0) 6/8 (75.0)
Convulsions >6 h after admission 32/178 (18.0) 1/15 (6.7) 2/8 (25.0)
Impaired consciousness 155/180 (86.1) 13/15 (86.7) 5/8 (62.5)
Comatose (BCS < 3) 106/180 (58.9) 14/15 (93.3)† 2/8 (25.0)
Deep breathing 86/180 (47.8) 12/15 (80.0)† 3/8 (37.5)
Severe anemia 113/179 (63.1) 13/15 (86.7)† 8/8 (100.0)†
Hemoglobinuria 33/180 (18.3) 5/15 (33.3) 2/8 (25.0)
Jaundice 28/179 (15.6) 3/15 (20.0) 3/8 (37.5)
Shock 16/180 (8.9) 4/15 (26.7)† 1/8 (12.5)
Number of severe malaria Criteriab 4 (3–6) 7 (6–7)† 4 (3–5)
Laboratory Results
Parasitemia (parasites/µL) 26 720 (2434–84 640) 6600 (360–108 520) 1460 (400–46 800)†
Hemoglobin (g/dL) 4.8 (3.2–6.5) 4.7 (2.8–5.0) 3.4 (2.6–3.6)†
White blood cell count 11.8 (7.6–19.3) 10.7 (5.2–20.0) 18.8 (8.7–24.1)
Platelet count 71 (38–128) 65 (40–133) 131 (67–243)
Glucose 6.7 (5.5–8.1) 6.9 (4.4–7.9) 6.0 (5.5–11.6)
Lactate 3.6 (2.1–6.4) 6.6 (3.7–10.6)† 4.3 (2.5–7.3)
Base excess −8 (−12, −4) −16 (−19, −12)† −8 (−11, −5)
Creatinine, µmol/L 32 (23–42) 39 (23–49) 28 (24–35)
BUN, mg/dL 16 (10–28) 28 (18–42)† 23 (10–43)
LDH, mU/mL 482 (313–699) 795 (482–1496)† 716 (529–902)†
Outcome
Mortality
In-hospital 15/180 (8.3) — —
6 moc 23/143 (16.1) — —
Neurologic disability at discharge 13/163 (8.0) — 0/7 (0.0)
Abbreviations: bpm, beats per minute; BUN, blood urea nitrogen; IQR, interquartile range; LDH, lactate dehydrogenase.
a Data are presented as median (IQR) or n (%).
b Criteria assessed: coma (BCS < 3), repeated seizures (>2 generalized seizures in 24 hours), respiratory distress (age-related tachypneawith sustained nasal flaring, deep breathing, or subcostal
retractions), prostration (unable to sit unsupported), acute kidney injury (as described previously [22]), jaundice, hypoglycemia (<2.2 mM), hyperlactatemia (>5 mmol/L), severe anemia (Hb< 5 g/dL),
shock.
c Children <5 years were observed for 6 months (n = 19 > 5 years, n = 16 lost to follow up, n = 2 withdrew).
† Indicates P < .05 between in-hospital deaths and surviving children; or post-discharge deaths and children known to survive to 6 months.
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testing was performed in 71 children at day 14 based on clinical
evidence of anemia/pallor at the time of follow up and/or anemia
at discharge. There was no signiﬁcant difference in hemoglobin
levels at day 14 between children who survived to 6-month follow
up and children who subsequently died (P = .248). There was no
difference between the number of severe malaria criteria at pre-
sentation between children who survived until 6-month follow
up and those who died after hospital discharge (P = .591; Table 1).
Association Between Biomarker Levels and Morbidity and Mortality
We explored the association between biomarkers and disease
severity across common manifestations of severe malaria. Elevated
levels of Ang-2, sFlt-1, and sTREM-1 were associated with derange-
ments in multiple organ systems at presentation including respira-
tory distress, severe anemia, and hemoglobinuria (P < .05). After
adjustment for lactate levels, the association between Ang-2, sFlt-
1, and sTREM-1 and respiratory distress was lost, but the association
between Ang-2 and sFlt-1 and severe anemia remained signiﬁcant.
Angiopoietin-2 and sTREM-1 were associated with disease severity,
with biomarker levels increasing with increased LOD score (P < .05,
test for trend). The CXCL10 and sICAM-1 were not associated with
individual or composite measures of disease severity.
Levels of Ang-2, CXCL10, sFlt-1, sTREM-1, and lactate at pre-
sentation were higher in children who subsequently died in-hos-
pital (n = 15 of 179; P < .001, P = .027, P = .004, P = .065, and
P = .008, respectively) (Figure 2). We examined the kinetics of
the biomarkers in children who died where a day 2 sample was
available for testing (n = 6). The Ang-2 and CXCL10 levels re-
mained elevated on day 2 in children who subsequently died
(P = .004 and P = .03 , respectively). Although sICAM-1 levels
were not higher at presentation among children who died in-hos-
pital, sICAM-1 levels were elevated on day 2 of hospitalization in
children who subsequently died compared with those who sur-
vived (P = .014).
Finally, we examined whether biomarker levels over hospitaliza-
tion were associated with all-cause mortality at 6-month follow up
(n = 8 deaths postdischarge). We compared biomarker levels on
each day of hospitalization in children discharged alive who survived
until 6-month follow up versus those who subsequently died. An-
giopoietin-2 was the only biomarker associated with postdischarge
mortality (Figure 4). Using an LMEmodel of log-transformed Ang-
2 concentration over time showed that longitudinal Ang-2 levels
were signiﬁcantly higher among patients who died postdischarge
compared with known survivors (P < .0001). At admission, Ang-2
Figure 2. Biomarker levels in survivors vs nonsurvivors and kinetics of biomarker recovery. Scatter plot showing the distribution and median of biomarker levels on each day
of hospitalization and at follow up (day 14). The median trajectory for survivors (black) and nonsurvivors (red) are shown. Inset depicts scatter plot of biomarker levels at
admission in survivors and nonsurvivors (Mann-Whitney U test, where *P < .05, **P < .01, ***P < .001). The dotted red line in the mortality scatter plot represents the Youden
index generated for that biomarker in the index population [14]. Abbreviations: CXCL10/IP-10, 10 kDa interferon γ-induced protein; sFlt-1, soluble FMS-like tyrosine kinase-1;
sICAM-1, soluble intercellular adhesion molecule-1; sTREM-1, soluble triggering receptor expressed on myeloid cells-1.
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levels in the highest quartilewere associated with a 1.2-fold increased
risk of death postdischarge (RR, 1.2; 95% CI, 1.0–1.4). The Ang-2
levels at admission had an AUC of 0.82 (95% CI, .71–.93) to predict
postdischarge death (P= .004). Because a total of 16 children were
lost to follow up, we performed a sensitivity analysis assuming ﬁrst
that all children lost to follow up survived and second that all chil-
dren lost to follow up died (including children over 5 years of age
that were not followed). Using both approaches, Ang-2 remained
signiﬁcantly associated with postdischarge mortality (P = .002 as-
suming all children with unknown outcome at 6 months survived;
P= .026 assuming all children with unknown outcome at 6 months
died). None of the other biomarkers were associated with postdi-
schargemortality in the sensitivity analysis. Therewere no differenc-
es in levels of biomarkers and neurodisability at discharge (P > .05
for all markers).
Biomarkers to Improve Clinical Prediction
To assess whether integrating biomarker data into pediatric dis-
ease severity scores could improve prediction, we compared the
AUC curves generated using the predictive probabilities derived
from logistic regression models including the LOD score with or
without the individual biomarkers. The model including LODS
alone had an AUC of 0.77 (95% CI, .67–.88). Models including
Ang-2 or sFlt-1 were signiﬁcantly better than LODS alone at
predicting in-hospital mortality with AUCs of 0.85 (95% CI,
.79–.90; P = .03) and 0.83 (95% CI, .77–.88, P = .03), respectively
(Figure 5A). Lactate, CXCL10, and sTREM-1 did not add value
to LODS (P > .05).
Using a complementary approach, we asked whether biomark-
ers could be added to LODS to generate a simple predictive clini-
cal/biomarker model of malaria outcome [14, 17]. Children with a
biomarker level in the highest quartile were at increased risk of
death compared with children in the bottom 3 quartiles. Children
with high Ang-2 (>5.75 ng/mL) and sFlt-1 (>4.08 ng/mL) levels
had an increased risk of in-hospital mortality with RR of 3.0
(95% CI, 1.3–7.0) and 2.4 (95% CI, 1.2–4.9), respectively. We as-
signed a value of “1” if children had Ang-2 or sFlt-1 levels in the
highest quartile or a value of “0” for levels in the bottom 3 quartiles,
and we incorporated these data into a revised biomarker-LOD
(bLOD) score. The LODS alone (score: 0–3) had an AUC of
0.77. A score with Ang-2 (score: 0–4) had a signiﬁcantly higher
AUC of 0.84 (P = .02). Adding sFlt-1 to the LOD score (score:
Table 2. Association Between Biomarker Levels by Quartile and Time to Clinical Recoverya
Biomarker
Quartile
Time to First Feed
(Hour)
Time to Fever
Resolution (Hour)
Time to Localize Pain
(Hour)
Time to BCS = 5
(Hour)
Time to First Sit
(Hour)
Duration Hospitalization
(Hour)
Angiopoietin-2 P = .032 P = .247 P = .804 P = .036 P = .002 P = .429
Q1 14.5 (10.0–23.3) 6.2 (0–22.9) 6.5 (0–14.9) 11.7 (5.8–19.8) 24.0 (13.0–46.2) 64.0 (60.2–82.8)
Q2 15.2 (8.0–29.0) 8.0 (0–35.6) 4.1 (0–11.8) 14.4 (7.0–25.4) 27.6 (15.4–65.6) 63.0 (57.9–81.4)
Q3 19.0 (10.0–39.6) 9.4 (2.0–26.0) 6.0 (0–16.4) 17.2 (8.2–38.7) 44.2 (24.4–70.2) 71.8 (60.3–88.6)
Q4 22.5 (10.1–37.1) 8.0 (0–33.3) 6.5 (0–12.0) 15.5 (8.5–32.0) 39.1 (26.8–65.6) 78.5 (59.0–103.0)
CXCL10 P = .474 P = .006 P = .617 P = .713 P = .172 P = .332
Q1 16.0 (9.1–39.1) 5.2 (0–14.3) 6.0 (0–15.1) 14.5 (8.3–33.8) 30.6 (15.0–62.0) 78.2 (61.8–97.8)
Q2 14.0 (8.5–35.0) 10.6 (0–30.1) 5.8 (0–17.0) 14.0 (7.0–29.0) 33.0 (19.0–58.8) 64.0 (59.7–83.9)
Q3 15.5 (9.9–21.1) 8.0 (0–20.7) 5.8 (0–10.3) 12.0 (6.0–18.0) 29.0 (18.0–62.8) 61.7 (56.5–79.0)
Q4 23.3 (11.8–43.4) 16.0 (5.8–41.5) 7.6 (0–14.8) 20.5 (10.8–39.5) 42.9 (25.4–72.0) 78.3 (61.1–102.7)
sFlt-1 P = .332 P = .325 P = .162 P = .760 P = .159 P = .949
Q1 16.1 (9.1–39.5) 7.0 (0–25.4) 6.3 (1.0–23.0) 15.5 (5.7–38.9) 24.7 (12.5–55.6) 63.0 (59.7–85.3)
Q2 17.8 (10.7–43.6) 7.2 (0–28.2) 6.0 (0–12.1) 14.5 (8.1–43.6) 38.7 (20.0–68.2) 68.8 (57.8–86.5)
Q3 16.3 (10.3–28.5) 10.0 (0–30.6) 4.1 (0–12.3) 14.0 (7.6–25.0) 34.3 (20.5–62.8) 75.4 (59.5–83.5)
Q4 12.8 (8.1–26.8) 9.0 (0–31.9) 6.0 (0–15.0) 13.5 (8.0–25.4) 45.0 (18.7–63.8) 68.4 (59.0–86.0)
sICAM-1 P = .112 P = .008 P = .088 P = .157 P = .009 P = .029
Q1 16.0 (10.1–36.2) 6.1 (0–25.7) 0 (0–11.9) 14.5 (7.0–32.1) 26.0 (15.0–62.0) 63.5 (59.0–86.0)
Q2 14.3 (8.5–23.8) 7.1 (0–15.8) 6.5 (0–11.3) 11.5 (6.5–21.6) 29.4 (16.7–48.1) 62.0 (59.0–79.5)
Q3 14.8 (9.6–27.7) 7.2 (0–24.6) 6.0 (0–14.2) 13.5 (8.1–21.8) 32.5 (17.8–59.9) 77.2 (60.5–84.0)
Q4 25.0 (10.2–45.3) 19.8 (3.1–47.9) 7.9 (0–18.1) 22.5 (8.5–45.3) 47.7 (27.9–80.4) 78.8 (61.3–126.7)
sTREM-1 P = .009 P = .949 P = .413 P = .018 P = .001 P = .225
Q1 12.7 (6.8–21.0) 9.4 (0–26.3) 5.7 (0–13.8) 12.3 (6.0–19.0) 25.1 (8.9–49.8) 62.0 (59.0–83.0)
Q2 16.0 (8.0–30.3) 6.6 (0–28.6) 6.0 (0–18.4) 12.2 (6.0–28.0) 24.5 (12.5–39.7) 63.5 (58.0–93.0)
Q3 17.8 (12.3–38.2) 8.3 (0–25.5) 5.3 (0–14.8) 16.0 (8.5–31.0) 46.2 (25.5–68.1) 78.5 (60.4–86.3)
Q4 17.8 (11.4–43.0) 6.8 (0–34.1) 7.6 (0–13.3) 14.5 (10.2–40.3) 41.2 (22.6–69.6) 76.0 (61.1–90.1)
Abbreviations: Ang-2, angiopoietin-2; BCS, Blantyre coma score; CXCL10/IP-10, 10 kDa interferon γ-induced protein; IQR, interquartile range; sFlt-1, soluble FMS-like tyrosine kinase-1; sICAM-
1, soluble intercellular adhesion molecule-1; sTREM-1, soluble triggering receptor expressed on myeloid cells-1.
a Data are presented as median (IQR). Datawere analyzed non-parametrically using the Jonkcheere-Terpstra test for ordered alternatives. Ang-2: Q1, ≤1.41 ng/mL; Q2, 1.42 to ≤3.00 ng/mL; Q3,
3.01 to ≤5.73 ng/mL; Q4, >5.74 ng/mL. CXCL10: Q1, ≤0.15 ng/mL; Q2, 0.16 to ≤0.52 ng/mL; Q3, 0.53 to ≤1.17 ng/mL; Q4, 1.18 ng/mL. sFlt-1: Q1, ≤0.79 ng/mL; Q2, 0.80 to ≤2.01 ng/mL; Q3,
2.02 to ≤4.07 ng/mL; Q4, >4.08 ng/mL. sICAM-1: Q1, ≤596.76 ng/mL; Q2, 596.77 to ≤737.82 ng/mL; Q3, 737.83 to ≤927.21 ng/mL; Q4, >927.22 ng/mL. sTREM-1: Q1, ≤0.13 ng/mL; Q2, 0.14
to ≤0.27 ng/mL; Q3, 0.28 to ≤0.52 ng/mL; Q4, >0.53 ng/mL.
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0–4) resulted in a trend towards a higher AUC of 0.83 (P = .06),
whereas bLOD score including both Ang-2 and sFlt-1 had the
highest AUC of 0.86 (95% CI, .81–.91). A LODS score >2 had a
sensitivity to predict in-hospital death of 73.3% with a speciﬁcity
of 73.8% and a positive and negative predictive value of 20.4% and
96.8%, respectively (Figure 5B). A bLOD score >2 had a sensitivity
and speciﬁcity to predict death of 93.3% and 58.5% with corre-
sponding positive and negative predictive values of 17.1% and
99.0%, respectively (Figure 5C).
DISCUSSION
In this study, we examined clinical and biomarker predictors of
short- and long-term mortality in Ugandan children with severe
malaria treated with intravenous artesunate. We validated a panel
of biomarkers previously associated with malaria mortality in an
independent population [14]. The Ang-2, CXCL10, and sFlt-1
were signiﬁcantly elevated at admission in children who died
in-hospital. Levels of the biomarkers decreased as children recov-
ered, with most biomarkers normalizing to day 14 levels by day 3
of hospitalization. Elevated levels of Ang-2, sTREM-1, CXCL10,
and sICAM-1 at admission were associated with prolonged clin-
ical recovery times. Furthermore, elevated levels of Ang-2 over
hospitalization were associated with postdischarge mortality.
Using 2 complementary approaches, Ang-2 and sFlt-1 were
shown to improve prognostic accuracy above LODS alone, where-
as lactate did not. Together, these data validate these biomarkers
as quantitative measures of disease severity that are associated
with clinical recovery, and they may have utility in assessing
both short- and long-term risk of death in children with severe
malaria.
In this study, we conﬁrm and extend reports from both adults
and children describing Ang-2 as a marker of disease severity and
mortality in severe malaria [12–17, 23, 24].The Ang-2 levels were
elevated in children who presented with respiratory distress, se-
vere anemia, and hemoglobinuria and were associated with the
LOD score. Children with higher Ang-2 levels at admission
took longer to regain full consciousness, sit unsupported, or
feed (Table 2). In addition, high Ang-2 levels were associated
with increased risk of death in-hospital and within 6-month fol-
low up. Children who died postdischarge showed an initial de-
crease in Ang-2 but had persistently higher Ang-2 levels on
day 4 of hospitalization (Figure 4). Together, these data support
the idea that endothelial activation is an important determinant
Figure 4. Angiopoietin-2 (Ang-2) levels over hospitalization in children who died
after hospital discharge compared with known survivors. Scatter plot with line con-
necting the median levels of Ang-2 during hospitalization in children who died post-
discharge, or those who survived until 6 months follow up, with the in-hospital
deaths included as a reference.
Figure 3. Venn diagram depicting the frequency of clinical prognostic signs associated with in-hospital and postdischarge mortality. Venn diagram illustrating the most
frequent presenting signs associated with (A) in-hospital mortality, and (B) postdischarge mortality assessed at 6 month follow-up. The percentages indicate the proportion of
the population with the combination of signs.
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of clinical outcome and recovery in severe malaria. More impor-
tantly, these data also suggest that persistent endothelial activa-
tion and dysfunction may predict and impact future survival.
Children who died postdischarge had clinical features sugges-
tive of hemolysis (severe anemia, elevated plasma LDH, clinical
jaundice), which may be associated with persistent endothelial
activation [25].Despite a limited number of deaths in this study,
we show that Ang-2 improved prediction over LODS alone
using logistic regression models or a simple scoring system to
predict outcome. These data are supported by a previous report
from Malawi, where Ang-2 added value to clinical predictors of
mortality, but lactate did not [17]. Angiopoietin-2 is a robust
biomarker that is readily detectable in serum, plasma, and
lysed whole blood [13, 14, 16, 17, 24, 26], making it one of the
most promising prognostic biomarkers identiﬁed to date.
Soluble FMS-like tyrosine kinase-1 is a splice variant of the
vascular endothelial growth factor receptor (VEGFR)-1 (Flt-1)
receptor. Soluble FMS-like tyrosine kinase-1 binds VEGF pre-
venting it from signaling. Soluble FMS-like tyrosine kinase-1 is
expressed bymonocytes and endothelium and is induced by hyp-
oxia and VEGF [27, 28].The role of sFlt-1 in critical illness is un-
clear; however, it may be involved in maintaining vascular
integrity by sequestering VEGF and preventing it from inducing
vascular permeability. Soluble FMS-like tyrosine kinase-1 levels
correlated with lactate and were associated with the presence of
respiratory distress, severe anemia, and hemoglobinuria at pre-
sentation. Furthermore, sFlt-1was associated with increased risk
of in-hospital mortality. Our ﬁndings are consistent with a report
of elevated sFlt-1 in severe malaria and in children with fatal se-
vere malarial anemia [14]. Soluble FMS-like tyrosine kinase-1 is
synergistically induced inmononuclear cells treated with comple-
ment C5a and malaria bioactive product pfGPI [29] and has been
implicated in the pathogenesis of placental malaria [30]. The
FLT1 genotype is under natural selection in malaria-endemic
areas [31]. Together, these ﬁndings support an important role
for sFlt-1 in malaria responses. Increased sFlt-1 levels have also
been associated with disease severity [32] and mortality in sepsis
[33], consistent with increased sFlt-1 expression in conditions
with systemic inﬂammation and vascular leak. Mechanistic stud-
ies will be required to elucidate whether increased sFlt-1 levels in
malaria are contributing to disease severity or are a consequence
of tissue hypoxia and/or increased VEGF expression [15, 34].
Intercellular adhesion molecule-1 binds parasitized erythrocytes
contributing to sequestration, microvascular occlusion, tissue hyp-
oxia, and endothelial dysfunction [35, 36]. Intercellular adhesion
molecule-1 is expressed on endothelium, monocytes, and lympho-
cytes and can be cleaved through ectodomain shedding by matrix
metalloproteinase-9 [37] in response to inﬂammatory stimuli, in-
cluding TNF [38]. Several groups have reported elevated sICAM-1
levels in severe [15,39–42]and fatal malaria [14,39]. In this cohort,
sICAM-1 was elevated at admission and decreased over the course
of hospitalization but remained elevated at day 4, which is consis-
tent with reports that sICAM-1 remains elevated for at least 1
month after severe malaria [40, 43]. Furthermore, elevated
sICAM-1 was associated with prolonged clinical recovery times,
including time to fever resolution, time to ﬁrst sit, and duration
of hospitalization. Although sICAM-1 was not higher at admission
in the children who died on the ﬁrst day of hospitalization, there
was a trend of increasing sICAM-1 levels on day 2 of hospitaliza-
tion in children who subsequently died in-hospital. These data are
consistent with sICAM-1 representing a marker of disease severity
in malaria.
The CXCL10/IP-10 is a proinﬂammatory chemokine that is a
prognostic marker in malaria, with studies reporting elevated
CXCL10 in both children and adults with fatal malaria [14,
44, 45]. Recent studies suggest CXCL10 may be involved in
Figure 5. The predictive ability of the Lambaréné Organ Dysfunction Score (LODS) to predict in-hospital mortality with or without host biomarkers. (A) Receiver operating
characteristic curves generated from the predictive probabilities of logistic regression models with in-hospital mortality as the dependent variable and LODS (black line), LODS
and angiopoietin-2 (Ang-2) (red line), or LODS and soluble FMS-like tyrosine kinase-1 (sFlt-1) (blue line) as independent variables. (B) Histogram showing the distribution of LOD
scores as a percentage of children who were discharged alive (black bars) vs those who died in-hospital (red bars). (C) Histogram showing the distribution of combined bio-
marker-LOD score incorporating as a percentage of children who were discharged alive (black bars) vs those who died in-hospital (red bars).
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the depletion of endothelial progenitor cells (EPCs) in malaria
[46]. In vitro studies implicated heme-induced apoptosis
of EPCs through TLR4-mediated CXCL10 expression [46]. En-
dothelial progenitor cells are important for microvascular re-
pair, and low levels of circulating EPCs have been reported in
Ghanaian children with cerebral malaria [47]. Furthermore,
CXCL10 has also been shown to exert an apoptotic effect on
human brain microvascular endothelial cells and neuroglia
cells in vitro [48]. In this cohort, CXCL10 levels were elevated
in children who died in-hospital, were associated with a pro-
longed time to fever resolution, and returned to baseline by
day 3 in survivors. We did not observe an association between
CXCL10 levels and speciﬁc manifestations of severe malaria (eg,
cerebral malaria), or neurologic outcomes, suggesting that ele-
vated CXCL10 levels are not speciﬁc to neurological manifesta-
tions of malaria but are associated with disease severity.
Soluble triggering receptor expressed on myeloid cells-1 is an
inﬂammatory protein recently described as a novel prognostic
marker in Ugandan children with severe malaria [14]. In this
study, we conﬁrmed that sTREM-1 is associated with disease
severity in pediatric severe malaria. The sTREM-1 levels at ad-
mission were associated with time to ﬁrst sit, time to regain
consciousness, and time to ﬁrst feed. Although sTREM-1 was
not signiﬁcantly associated with mortality in this study, we had
limited power given the small sample size. The sTREM-1 levels
were increased in children with respiratory distress, severe ane-
mia, and hemoglobinuria at presentation and were associated
with the LOD score.
This study prospectively validated a panel of mortality biomark-
ers in the context of a clinical trial. There were several strengths to
this study including longitudinal sampling, which enabled us to
examine the kinetics of biomarker recovery in survivors. The col-
lection of detailed clinical information enabled us to evaluate the
association between biomarkers and recovery times in survivors.
We were able to evaluate clinical and biochemical predictors asso-
ciated with late death in pediatric malaria. Although mortality in-
hospital was characterized by multiorgan dysfunction, acidosis,
endothelial activation, and inﬂammatory biomarkers suggestive
of a progressive and overwhelming systemic inﬂammatory re-
sponse syndrome, children who died postdischarge were all ad-
mitted with severe anemia, and they were more likely to have
jaundice, elevated LDH, lower parasitemia, and persistent ele-
vations in Ang-2 over hospitalization. We speculate that chil-
dren who died postdischarge had chronic hemolysis, perhaps
mediated through repeated malaria infections, because children
with known hemoglobinopathies were excluded from the trial.
Although we cannot conﬁrm the cause of death in these chil-
dren, rebound anemia and/or infection are likely causes.
This study was not powered to detect differences in mortality
between study arms and included a relatively small number of
fatal cases, sowewere limited in our ability to performmultivariate
analyses to examine independent predictors of in-hospital and
postdischarge mortality. In addition, we only followed children
less than 5 years out to 6 months for cognitive testing (19 children
were excluded from follow up according to the study protocol),
and 16 children were lost to follow up. It is possible that some
of the children lost to follow up represent additional study deaths.
We performed a sensitivity analysis assuming that all of these chil-
dren died and all survived, and the results remained signiﬁcant.
Because many health centers in resource-limited settings lack ad-
equate diagnostics to investigate the etiology of illness in children
presenting with fever, it will be important to validate this panel of
biomarkers (1) in the context of both malarial and nonmalarial
fever and (2) to evaluate whether these biomarkers can predict
the development of complications to guide referral. Additional val-
idation studies will be required to assess (1) whether biomarkers
could be used before hospital discharge to identify children in
need of more intensive follow up and (2) how information from
fast recovery (eg, venous lactate) versus slower recovery (eg, Ang-2,
sICAM-1) biomarkers could be integrated for continual risk as-
sessment over hospitalization.
CONCULSIONS
The results from this study conﬁrm and extend previous reports
that systemic endothelial activation is associated with morbidity
and mortality in malaria. In this study, we demonstrate that host
biomarkers represent objective measures to monitor clinical re-
covery over hospitalization. Furthermore, persistent endothelial
activation predicted both short- and long-term survival in chil-
dren with severe malaria. These ﬁndings suggest a need for
more intensive follow up in children presenting with anemia
and evidence of persistent endothelial activation. Further vali-
dation of these biomarkers across ﬁeld-sites in malaria-endemic
areas are required to evaluate whether host biomarkers have
utility in identifying children most likely to beneﬁt from target-
ed interventions. Finally, because some of these markers (for ex-
ample, Ang-2) are critical regulators of endothelial activation
and integrity, they provide a direct measure of the degree of un-
derlying microvascular dysfunction and represent novel poten-
tial targets for directed intervention. Ultimately, strategies that
reduce inﬂammation and improve endothelial function may re-
duce morbidity and mortality associated with severe malaria.
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